about
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon responseAdvances in the treatment of chronic myeloid leukemia.Zebrafish screen identifies novel compound with selective toxicity against leukemia.Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiashRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemiaβ-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsA role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemiaPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.Age-related mutations and chronic myelomonocytic leukemia.Pushing the limits of targeted therapy in chronic myeloid leukaemia.Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic LiabilitiesBCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.What challenges remain in chronic myeloid leukemia research?Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade.The new role of microRNAs in cancer.Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cellsCD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibodyNuclear-Cytoplasmic Transport Is a Therapeutic Target in MyelofibrosisCoordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cellsEnergy metabolism and drug response in myeloid leukaemic stem cellsDasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
P50
Q30496174-F6D76353-B685-419B-A97D-2322E4EABA4CQ33782332-BBC6DED8-575F-4282-953B-B2A7C3AF4BB5Q34002977-4498B0C3-0D5A-48FD-8C79-294D6FB3AFF0Q34227256-6225B4D3-655C-410D-8976-3B80B38E3B21Q34846910-5E429581-AA33-4E0A-A9B4-82421BA68A27Q35102414-11769F61-1314-4373-8B78-E8AA5EE1A72FQ35171271-EBBB7E1C-6564-40FB-B2A7-636A5162F8A4Q35805105-432A8CDE-9F9E-4EFE-A157-8EDAD7EE68F6Q36210636-721B355D-F04B-4134-89DA-0A8D65A4C9EBQ36362945-6B764397-4116-46AB-86CC-6CB94698061CQ36384790-59830D1E-5255-4480-8EFA-3D078FE722D4Q36542821-A6863F30-7DE1-4FB9-87D4-C62EEA1C676AQ37073009-D10EFAFE-9C05-4BA7-9D9C-B91649C21192Q37200863-61BF56DE-4E7A-4CDC-8523-802C1DB3C565Q37389361-7A246720-3652-4106-A4DF-95237C26ECCAQ37395779-291959A3-E042-465E-A971-D1ECC9AD5D0AQ38028778-00AF7EF3-602A-4642-BD72-C75823705BBFQ38260343-FC93745B-BBD1-436B-A05C-E1AE29111740Q38364773-C6CC3F03-8F0B-4475-BB28-292B787B07CAQ38782370-BA8B98A5-EBE5-48C5-852D-B25E405717C2Q41980844-F27AA815-813C-48E5-9CB3-10AF673B7566Q42935464-DF5CC9DC-F84E-4777-A330-C7F1590C7E2EQ47347243-DFD38092-2FA0-4FE5-92AC-2FC591B0A538Q51798231-2AD68EB3-064F-4B0B-9516-87EB0565AED6Q80061597-C91412DF-A4DA-4CD7-B7E8-7B037A7F0E6AQ81119228-2A4FE6F2-D076-4797-89FF-7B2B919E327AQ90622530-6686EBD1-2887-4EC5-8EB3-C13784CE766DQ92932888-BE1EC160-1886-4893-84E5-F8B84CC6D51CQ93007141-28354FD0-DF9A-4F04-8A41-F306DEDE34F6Q94686561-17E6859F-F509-4B4E-845F-264C60ED8390
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Anna M Eiring
@ast
Anna M Eiring
@en
Anna M Eiring
@es
Anna M Eiring
@nl
type
label
Anna M Eiring
@ast
Anna M Eiring
@en
Anna M Eiring
@es
Anna M Eiring
@nl
prefLabel
Anna M Eiring
@ast
Anna M Eiring
@en
Anna M Eiring
@es
Anna M Eiring
@nl
P1153
7801316366
P21
P31
P496
0000-0001-6533-9150